Moreover, many rappers come from impoverished neighborhoods and realize that, if they don’t seize the opportunity to make music that sells while they have the chance, they may never get another ...

The senator representing Delta North senatorial district in the upper chamber of the National Assembly, Senator Ned Nwoko, has cautioned people of Delta North to remain security conscious ...

A sleep study found that 57% of people hit the snooze button. While it's not terrible, a neuroscientist explains what it does to your sleep. When I was pregnant I learned about gentle parenting ...

Chibuzo Nwoko has signed a first pro deal with Fulham. After signing for the club at Under-12s level from rivals Chelsea, Nwoko has risen through the Fulham's ranks and has become a key player for ...

Naturally, there are some big choices to be made during Frostpunk 2's campaign, and a short-lived character named Lily May becomes the personification of those choices and how they've affected ...

Lively stars as the lead character, Lily, while Baldoni stars as a man named Ryle Kincaid (yes, really!). Lily falls into a troubled romantic, and ultimately abusive, relationship with Ryle.

Eli Lilly has become a household name thanks to breakthrough diabetes and obesity care medicines. The stock has trounced the broader market over the past year, and shares have become a bit pricey.

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Earnings Report 1.454 USD Q3 2024 Earnings Release 10/30/2024 Earnings Report 5.436 USD Q4 2024 Earnings Release 01/30/2025 Earnings Report 5.367 USD Q1 2025 Earnings Release 04/24/2025 Earnings ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests ...